Back to Search
Start Over
PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects
- Source :
- BRITISH JOURNAL OF HAEMATOLOGY, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Publication Year :
- 2000
- Publisher :
- WILEY-BLACKWELL, 2000.
-
Abstract
- Impaired fibrinolysis as a result of increased plasminogen activator inhibitor-1 (PAI-1) levels in plasma is a common finding in patients with deep vein thrombosis (DVT). A 4G/5G polymorphism in the promoter region of the PAI-1 gene has been reported to influence the levels of PAI-1. The 4G allele was found to be associated with higher plasma PAI-1 activity (act), but contradictory results on the incidence of the 4G allele in DVT patients have been reported. The aim of this study was to analyse whether the PAI-1 promoter 4G/5G genotype increases the risk of venous thrombosis in subjects with thrombophilic defects, and to determine the distribution of the PAI-1 4G/5G genotype and its relation to plasma PAI-1 levels in 190 unrelated patients with DVT in comparison with a control group of 152 healthy subjects. No differences between the 4G/5G allele distribution in the DVT group (0.43/0.57) and in the control group (0.42/0.58) were observed. However, the presence of the 4G allele significantly increased the risk of thrombosis in patients with other thrombophilic defects. Significantly higher PAI-1 levels were observed in DVT patients than in the controls. Our results also showed significant differences in the plasma levels of PAI-1 antigen (ag) and PAI-1 act among the 4G/5G genotypes in DVT patients. A multivariate analysis revealed that, in the DVT group, PAI-1 ag levels were influenced by the 4G allele dosage, triglyceride levels and body mass index (BMI). The influence of the 4G allele dosage on PAI-1 levels was independent of the triglyceride levels and BMI. In the control group, no significant correlation between PAI-1 levels and 4G allele dosage was observed. In conclusion, the PAI-1 promoter polymorphism was found to have an influence on PAI-1 levels in DVT patients and on the risk of venous thrombosis in subjects with other genetic thrombophilic defects.
- Subjects :
- Adult
Blood Glucose
Male
medicine.medical_specialty
Pathology
Genotype
medicine.medical_treatment
Thrombophilia
Gastroenterology
Statistics, Nonparametric
chemistry.chemical_compound
Risk Factors
Internal medicine
Plasminogen Activator Inhibitor 1
Fibrinolysis
medicine
Humans
Genetic Predisposition to Disease
Antigens
Risk factor
Allele
Promoter Regions, Genetic
Triglycerides
Venous Thrombosis
Chi-Square Distribution
business.industry
Thrombin
Hematology
Middle Aged
medicine.disease
Thrombosis
Venous thrombosis
chemistry
Case-Control Studies
Tissue Plasminogen Activator
Plasminogen activator inhibitor-1
Female
business
Protein C
Subjects
Details
- ISSN :
- 00071048
- Database :
- OpenAIRE
- Journal :
- BRITISH JOURNAL OF HAEMATOLOGY, r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe, instname
- Accession number :
- edsair.doi.dedup.....f89788e621c0e4bdf35a41481719239b